Trim 30-40% into rally; $102 hard stop with Q2 2026 re-engagement criteria
The 30-40% trim strategy captures asymmetric downside protection if the $104.72/$105.01 confluence zone breaks (saving 3-4% capital on trimmed portion), costs approximately 1% of foregone dividend carry in the bull path, and respects both the dividend-carry constraint (which rules out full exit) and the escalation mandate (which requires 30-40% rather than the neutral analyst's 20-30%). Full sell is rejected because $7.4B FY25 FCF, 1.6x dividend coverage, 0.58 beta, and 54-year Aristocrat status provide a genuine defensive floor validated by the 9/1 Underweight generating +1.0% alpha. The aggressive analyst's 17.35x forward P/E case is a 2027-2028 normalization story, not actionable for Q4 2026 given the current technical regime testing rather than holding the confluence zone.
| Position | Action |
|---|---|
| Rally to $107-$108 (10 EMA) | Trim 30-40% of position |
| No relief bounce materializes | Trim at $105.23 within 1-2 weeks |
| Confluence zone ($104.72/$105.01) holds and rally materializes | Retain 60-70% core position to capture dividend carry |
| Price breaks below $102.00 on retained core | Hard stop executed (1.5x ATR below 50/200 SMA confluence) |
Abbott's $105 pullback is a triple-SMA confluence support entry with a forward P/E of 17.35x that is artificially cheap relative to normalizing earnings power, a freshly FDA-cleared TactiFlex Duo in the fastest-growing cardiac segment, and a competitor self-destructing — offering a 22:1 near-term risk/reward on a 54-year dividend compounder.
| Indicator | Value | Signal |
|---|---|---|
| Price (Close) | $105.23 | neutral |
| 10 EMA | $108.90 | bearish |
| 50 SMA | $104.72 | neutral |
| 200 SMA | $105.01 | neutral |
| RSI (14) | 40.15 | bearish |
| MACD Line | 0.42 | bearish |
| MACD Signal | 1.88 | bearish |
| MACD Histogram | -1.46 | bearish |
| Bollinger Middle (20 SMA) | $111.51 | bearish |
| Bollinger Upper | $118.04 | neutral |
| Bollinger Lower |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Controlled pullback to $98-$100 with RSI oversold (<32)
Then: Re-engage/add to position
EV: $112-$117 on a reclaim of the 10 EMA · concedes: Bear's TTM P/E of 34x is currently accurate, though bull argues it's artificially depressed by acquisition step-up D&A and one-time integration costs; Net debt did jump from $4.4B to $27.2B and tangible book value turned negative — though bull frames this as deliberate capital allocation, not deterioration; Operating margin did compress to 12% in Q1 2026 from 18.5% — though bull attributes this entirely to integration noise below the gross line; Litigation overhang (Similac NEC, Libre class actions) exists and is probability-weighted — bull frames as cyclical headline risk, not existential threat; Bear's technical signals (MACD histogram expanding negative, price below 10 EMA) are real and accurate descriptions of current momentum; Bear's HOLD recommendation reflects genuine ambiguity in the technicals, which bull interprets as consolidation rather than distribution
ABT faces a momentum regime change, a severely leveraged balance sheet from the $20B acquisition, and a crowded competitive landscape for its key growth catalyst—making the current entry point asymmetric to the downside and warranting a defensive HOLD rather than a BUY.
· concedes: 54-year dividend streak (real, but it's the floor, not the catalyst); Fresh FDA approval in a fast-growing segment (real, but unproven commercially); SMA confluence support at $104.72/$105.01 (real, but those supports have failed before — next support is $94-$99, not $100); Forward P/E 'cheapness' at 17.35x (real, if integration works — but 'big ifs have a habit of failing')
→ vs conservative: Net debt 'scare tactic' misrepresents debt burden; $7.4B annual FCF pays off $27.2B in 3.7 years vs 7+ year conservative estimate
→ vs conservative: Forward P/E of 17.35x is BOTTOM of historical range, not justification for SELL; forward EPS nearly double TTM ($6.06 vs $3.09)
→ vs conservative: Technical indicators (RSI 40, MACD -1.46, price below 10 EMA) ignore triple-confluence support at $105—'coiled spring' not breakdown setup
→ vs conservative: Plan to sell at $105 and buy back at $98-$100 is market timing, not risk management; catalyst may not allow pullback
→ vs conservative: Competitor Boston Scientific is 'literally self-destructing' in EP space via cyberattack and weak guidance, creating opportunity Abbott just captured with TactiFlex Duo
| $104.99 |
| neutral |
| ATR (14) | 2.78 | neutral |
| VWMA | $111.52 | bearish |
Support: 104.72 · 104.99 · 105.01 · 100 | Resistance: 108.9 · 111.5 · 111.51 · 111.52 · 116.67
ABT is in a corrective pullback with price sitting at major confluence support ($104.72-$105.01 zone). Short-term momentum is bearish as MACD histogram expanded to -1.46 (turned negative on 2026-08-26), RSI at 40.15 indicates neutral-to-weak territory with room to fall further, and price is riding the lower Bollinger Band ($104.99). VWMA at $111.52 is $6.30 above current price, confirming heavy overhead supply. Long-term structure remains intact as price holds above the 200-day SMA ($105.01). HOLD stance warranted; actionable signals require either reclaim of $108.90 (10 EMA) for longs or breakdown below $104.50 for shorts.
Market Cap
$182.1B
P/E (TTM)
34.06x
Forward P/E
17.35x
PEG Ratio
1.99
Price/Book
3.56x
Dividend Yield
2.39%
Beta
0.59
52W Range
$81.97 – $137.49
50D MA
$104.60
200D MA
$106.18
Revenue (TTM)
$46.58B
Net Income (TTM)
$5.40B
EPS (TTM)
$3.09
Forward EPS
$6.06
Operating Margin (TTM)
14.7%
Profit Margin (TTM)
11.6%
ROE
10.6%
ROA
5.3%
Total Assets
$110.4B
Total Equity
$52.0B
Total Debt
$34.0B
Net Debt
$27.2B
Debt/Equity
63.2
Current Ratio
1.38
Goodwill + Intangibles
$53.1B
Tangible Book Value
-$1.0B
FCF (2025)
$7.40B
OCF (2025)
$9.57B
Capex (2025)
$2.17B
Dividends Paid (2025)
$4.12B
Buybacks (2025)
$893M
Diluted Shares
1.74B
Book Value Per Share
$29.54
Revenue Growth (Q1 26 YoY)
+7.7%
Net Debt / FCF
3.7x
Revenue (2025)
$44.33B
Revenue (2024)
$41.95B
Revenue (2023)
$40.11B
Revenue (2022)
$43.65B
Net Income (2025)
$6.52B
Net Income (2024)
$13.40B
Diluted EPS (2025)
$3.72
Diluted EPS (2024)
$7.64
Operating Margin (2025)
18.2%
Gross Margin
56.6%
Strengths
Concerns
Abbott completed a transformational ~$20B acquisition in Q1 2026, causing net debt to jump from ~$4.4B to $27.2B, goodwill to balloon from $24B to $35.2B, and temporarily depressing TTM EPS to $3.09 with operating margins compressing to ~12%. The company remains a strong cash generator ($7.40B FCF, $9.57B OCF in 2025) with healthy fundamentals and an attractive forward P/E of 17.35x (implying normalized EPS of $6.06), suggesting significant recovery potential as deal integration and deleveraging progress over the next 4-8 quarters.
Macro: Fed policy: No rate cuts in 2026 priced at 93% (up +4.0pp week-over-week); all '≥6 cuts' markets at 0%. US recession by end-2026 priced at only 8% (soft landing/continued expansion). Higher-for-longer stance supports defensive cash flows with predictable recurring revenue from devices, diagnostics, nutrition, and established pharma. No notable tariff, regulatory, or FX shocks this week; European consumer staples expected to underperform creates slight negative for international nutrition exposure but largely offset by U.S. mix. ABT earnings multiple supported; unlikely to see hawkish sell-off shock.